Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2012

Open Access 01-12-2012 | Research article

Innate immune properties of selected human neuropeptides against Moraxella catarrhalis and nontypeable Haemophilus influenzae

Authors: Daria Augustyniak, Adam Jankowski, Paweł Mackiewicz, Agnieszka Skowyra, Jan Gutowicz, Zuzanna Drulis-Kawa

Published in: BMC Immunology | Issue 1/2012

Login to get access

Abstract

Background

Considerable evidence supports the concept of active communication between the nervous and immune systems. One class of such communicators are the neuropeptides (NPs). Recent reports have highlighted the antimicrobial activity of neuropeptides, placing them among the integral components of innate immune defense. This study examined the action of four human neuropeptides: calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), substance P (SP) and somatostatin (SOM), which are accessible in the upper respiratory tract, against two human-specific respiratory pathogens. We studied: (i) neuropeptide-mediated direct antibacterial activity exerted against Moraxella catarrhalis and nontypeable Haemophilus influenzae, and (ii) indirect immunomodulatory role of these neuropeptides in the neutrophil-mediated phagocytosis of indicated pathogens.

Results

We found that 100 micromolar concentrations of CGRP, NPY, SP, and SOM effectively permeabilized bacterial membranes and showed (except SOM) bactericidal activity against both pathogens. SOM acted only bacteriostatically. However the killing efficacy was dependent on the bactericidal assay used. The rank order of killing NP effect was: NPY ≥ CGRP > SP >> SOM and correlated with their potency to permeabilize bacterial membranes. The killing and permeabilization activity of the analyzed NPs showed significant correlation with several physicochemical properties and amino acid composition of the neuropeptides. M. catarrhalis was more sensitive to neuropeptides than nontypeable H. influenzae.
The immunomodulatory bimodal effect of physiological concentrations of CGRP, NPY, and SP on the phagocytic function of human neutrophils against M. catarrhalis and H. influenzae was observed both in the ingestion (pathogen uptake) and reactive oxygen species generation stages. This effect was also dependent on the distinct type of pathogen recognition (opsonic versus nonopsonic).

Conclusions

The present results indicate that neuropeptides such as CGRP, NPY, and SP can effectively participate in the direct and indirect elimination of human-specific respiratory pathogens. Because the studied NPs show both direct and indirect modulating antimicrobial potency, they seem to be important molecules involved in the innate host defense against M. catarrhalis and nontypeable H. influenzae.
Appendix
Available only for authorised users
Literature
1.
Sternberg EM: Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol. 2006, 6: 318-328. 10.1038/nri1810.PubMedPubMedCentralCrossRef
2.
Brogden KA, Guthmiller JM, Salzet M, Zasloff M: The nervous system and innate immunity: the neuropeptide connection. Nat Immunol. 2005, 6: 558-563.PubMed
3.
Levite M: Neuropeptides by direct interaction with T cells induce cytokine secretion and break the commitment to a distinct T helper phenotype. PNAS. 1998, 95: 12544-12549. 10.1073/pnas.95.21.12544.PubMedPubMedCentralCrossRef
4.
Cuesta MC, Quintero L, Pons H, Suarez-Roca H: Substance P and calcitonin gene-related peptide increase IL-1β, IL-6 and TNF-α secretion from human peripheral blood mononuclear cells. Neurochem Int. 2002, 40: 301-306. 10.1016/S0197-0186(01)00094-8.PubMedCrossRef
5.
Ding W, Stohl LL, Wagner JA, Granstein RD: Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol. 2008, 181: 6020-6026.PubMedPubMedCentralCrossRef
6.
Dunzendorfer S, Kaser A, Meierhofer C, Tilg H, Wiedermann CJ: Peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J Immunol. 2001, 166: 2167-2172.PubMedCrossRef
7.
Ahmed AA, Wahbi AH, Nordlin K: Neuropeptides modulate a murine monocyte/macrophage cell line capacity for phagocytosis and killing of Leishmania major parasites. Immunopharmacol Immnotoxicol. 2001, 23: 397-409. 10.1081/IPH-100107339.CrossRef
8.
Bedoui S, Kromer A, Gebhardt T, Jacobs R, Raber K, Dimitrijevic M, Heine J, von Hörsten S: Neuropeptide Y receptor-specifically modulates human neutrophil function. J Neuroimmunol. 2008, 195: 88-95. 10.1016/j.jneuroim.2008.01.012.PubMedCrossRef
9.
Delgado M, Ganea D: Anti-inflammatory neuropeptides: A new class of endogenous immunoregulatory agents. Brain Behavior and Immunity. 2008, 22: 1146-1151. 10.1016/j.bbi.2008.06.001.CrossRef
10.
Elenkov IJ, Wilder RL, Chousos GP, Vizi ES: The sympathetic nerve – an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000, 52: 595-638.PubMed
11.
Chanez P, Springall D, Vignola AM, Moradoghi-Hattvani A, Polak JM, Godard P, Bousquet J: Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med. 1998, 158: 985-990.PubMedCrossRef
12.
Hellström S, Goldie P: Mechanisms ofotitis mediadevelopment. Involvement of neurogenic inflammation. Otolaryngol Clin North Am. 1991, 24: 829-834.PubMed
13.
Hauser-Kronenberg C, Hacker GW, Muss W, Saria A, Albegger K: Autonomic and peptidergic innervations of human nasal mucosa. Acta Otolaryngol Stockh. 1993, 113: 387-393. 10.3109/00016489309135831.CrossRef
14.
Figueroa JM, Mansilla E, Suburo AM: Innervation of nasal turbinate blood vessels in rhinitic and nonrhinitic children. Am J Respir Crit Care Med. 1998, 157: 1959-1966.PubMedCrossRef
15.
Basak S, Dikicioglu E, Turkutanit S, Sarierler M: Early and late effects of capsaicin pretreatment inotitis mediawith effusion. Otol Neurotol. 2005, 26: 344-350. 10.1097/01.mao.0000169775.61786.43.PubMedCrossRef
16.
Belvisi MG: Overview of the innervations of the lung. Curr Opin Pharmacol. 2002, 2: 211-215. 10.1016/S1471-4892(02)00145-5.PubMedCrossRef
17.
Schwarz H, Vilinger PM, von Kempis J, Lotz M: Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol. 1994, 51: 53-61. 10.1016/0165-5728(94)90128-7.PubMedCrossRef
18.
Ho W-Z, Lai J-P, Zhu X-H, Uvaydova M, Douglas SD: Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol. 1997, 159: 5654-5660.PubMed
19.
Wang H, Xing L, Li W, Hou L, Guo J, Wang X: Production and secretion of calcitonin gene-related peptide from human lymphocytes. J Neuroimmunol. 2002, 130: 155-162. 10.1016/S0165-5728(02)00221-7.PubMedCrossRef
20.
Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol. 2005, 3: 238-250. 10.1038/nrmicro1098.PubMedCrossRef
21.
Kowalska K, Carr DB, Lipkowski AW: Direct antimicrobial properties of substance P. Life Sci. 2002, 71: 747-750. 10.1016/S0024-3205(02)01740-X.PubMedCrossRef
22.
Hansen CJ, Burnell KK, Brogden KA: Antimicrobial activity of substance P and neuropeptide Y against laboratory strains of bacteria and oral microorganisms. J Neuroimmunol. 2006, 177: 215-218. 10.1016/j.jneuroim.2006.05.011.PubMedCrossRef
23.
El Karim IA, Linden GJ, Orr DF, Lundy FT: Antimicrobial activity of neuropeptides against a range of microorganisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol. 2008, 200: 11-16. 10.1016/j.jneuroim.2008.05.014.PubMedCrossRef
24.
De Vries SP, Bootsma HJ, Hays JP, Hermans PW: Molecular aspects of Moraxella catarrhalis pathogenesis. Microbiol Mol Biol Rev. 2009, 73: 389-406. 10.1128/MMBR.00007-09.PubMedPubMedCentralCrossRef
25.
Nizet V, Colina KF, Almquist JR, Rubens CE, Smith AL: A virulent nonencapsulated Haemophilus influenza. J Infect Dis. 1996, 173: 180-186. 10.1093/infdis/173.1.180.PubMedCrossRef
26.
Murphy TF, Bakaletz LO, Smeesters PR: Microbial interactions in the respiratory tract. Pediatr Infect Dis. 2009, 28 (10 suppl): S121-S126.CrossRef
27.
Murphy TF, Brauer AL, Grant BJ, Sethi S: Moraxella catarrhalisin chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med. 2005, 172: 195-199. 10.1164/rccm.200412-1747OC.PubMedPubMedCentralCrossRef
28.
Moghaddam SJ, Clement CG, De la Garza MM, Zou X, Travis EL, Young HW, Evans CM, Tuvim MJ, Dickey BF: Haemophilus influenzaelysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respire Cell Mol Biol. 2008, 38: 629-638. 10.1165/rcmb.2007-0366OC.CrossRef
29.
Mukundan D, Ecevit Z, Patel M, Mars CF, Gilsdorf JR: Pharyngeal colonization dynamics ofHaemophilus influenzaeandHaemophilus haemolyticusin healthy adult carriers. J Clin Microbiol. 2007, 45: 3207-3217. 10.1128/JCM.00492-07.PubMedPubMedCentralCrossRef
30.
Heiniger N, Spaniol V, Troller R, Vischer M, Aebi C: A reservoir ofMoraxella catarrhalisin human pharyngeal lymphoid tissue. J Infect Dis. 2007, 196: 1080-1087. 10.1086/521194.PubMedCrossRef
31.
Billal DS, Hotomi M, Suzumoto M, Yamauchi K, Kobayashi I, Fujihara K, Yamanaka N: Rapid identification of nontypeable and serotype bHaemophilus influenzaefrom nasopharyngeal secretions by the multiplex PCR. Int J Pediatr Otorhinolaryngol. 2007, 71: 269-274. 10.1016/j.ijporl.2006.10.009.PubMedCrossRef
32.
Lehrer RI, Rosenman M, Harwiq SS, Jackson S, Eisenhauer P: Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods. 1991, 137: 167-173. 10.1016/0022-1759(91)90021-7.PubMedCrossRef
33.
Hoover DM, Boulegue C, Yang D, Oppenheim JJ, Tucker K, Lu W, Lubkowski J: The structure of human macrophage inflammatory protein-3α/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human β-defensins. J Biol Chem. 2002, 277: 37647-37654. 10.1074/jbc.M203907200.PubMedCrossRef
34.
Lehrer RJ, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME: Interaction of human defensins withEscherichia coli. Mechanism of bactericidal activity. J Clin Invest. 1989, 84: 553-561. 10.1172/JCI114198.PubMedPubMedCentralCrossRef
35.
Starner TD, Barker CK, Jia HP, Kang Y, McCray PB: CCL20 is an inducible product of human airway epithelia with innate immune properties. Am J Respir Cell Mol Biol. 2002, 29: 627-633.CrossRef
36.
Lamprou I, Mamali I, Dallas K, Fertakis V, Lampropoulou M, Marmaras VJ: Distinct signaling pathways promote phagocytosis of bacteria, latex beads and lipoppolysaccharide in medfly haemocytes. Immunology. 2007, 121: 314-327. 10.1111/j.1365-2567.2007.02576.x.PubMedPubMedCentralCrossRef
37.
Tecle T, White MR, Gantz D, Crouch EC, Hartshorn KL: Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J Immunol. 2007, 178: 8046-8052.PubMedCrossRef
38.
Allen RC: Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 1986, 133: 449-493.PubMedCrossRef
39.
Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A: Protein Identification and Analysis Tools on the ExPASy Server. In The Proteomics Protocols Handbook. Volume 112. 2005, 531-552.
40.
Grantham R: Amino acid difference formula to help explain protein evolution. Science. 1974, 185: 862-864. 10.1126/science.185.4154.862.PubMedCrossRef
41.
Kyte J, Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982, 157: 105-132. 10.1016/0022-2836(82)90515-0.PubMedCrossRef
42.
Zhao G, London E: An amino acid “transmembrane tendency” scale that approaches the theoretical limit to accuracy for prediction of transmembrane helices: relationship to biological hydrophobicity. Protein Sci. 2006, 15: 1987-2006. 10.1110/ps.062286306.PubMedPubMedCentralCrossRef
43.
Deleage G, Roux B: An algorithm for protein secondary structure prediction based on class prediction. Protein Engineering. 1987, 1: 289-294. 10.1093/protein/1.4.289.PubMedCrossRef
44.
Rice P, Longden I, Bleasby A: EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet. 2000, 16: 276-277. 10.1016/S0168-9525(00)02024-2.PubMedCrossRef
45.
Dathe M, Wieprecht T: Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta. 1999, 1462: 71-87. 10.1016/S0005-2736(99)00201-1.PubMedCrossRef
46.
Ichinose M, Sawada M: Enhancement of phagocytosis by calcitonin gene-related peptide (CGRP) in cultured mouse peritoneal macrophages. Peptides. 1996, 17: 1405-1414. 10.1016/S0196-9781(96)00198-2.PubMedCrossRef
47.
Powers J-PS, Hancock REW: The relationship between peptide structure and antibacterial activity. Peptides. 2003, 24: 1681-1691. 10.1016/j.peptides.2003.08.023.PubMedCrossRef
48.
Sánchez-Gómez S, Lamata M, Leiva J, Blondelle SE, Jerala R, Andrä J, Brandenburg K, Lohner K, Moriyón I, Martínez-de-Tejada G: Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol. 2008, 8: 1-9. 10.1186/1471-2180-8-1.CrossRef
49.
Dakhama A, Park J-W, Taube Ch, El Gazzar M, Kodama T, Miyahara N, Takeda K, Kanehiro A, Balhorn A, Joetham A, Loader JE, Larsen G, Gelfand EW: Alteration of airway neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol. 2005, 288: L761-L770.PubMedCrossRef
50.
Chu HW, Kraft M, Krause JE, Rex MD, Martin RJ: Substance P and its receptor neurokinin 1 expression in asthmatic airways. J Allergy Clin Immunol. 2000, 106: 713-722. 10.1067/mai.2000.109829.PubMedCrossRef
51.
Killough SA, Lundy FT, Irwin CR: Substance P expression by human dental pulp fibroblasts: a potential role in neurogenic inflammation. J Endod. 2009, 35: 73-77.PubMedCrossRef
52.
Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G: In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents againstPseudomonas aeruginosa. J Antimicrob Chemother. 1999, 44: 641-645. 10.1093/jac/44.5.641.PubMedCrossRef
53.
Joly S, Maze C, McCray PB, Guthmiller JM: Human β-defensisn 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol. 2004, 42: 1024-1029. 10.1128/JCM.42.3.1024-1029.2004.PubMedPubMedCentralCrossRef
54.
Schelburne CE, Coulter WA, Olguin D, Lantz MS, Lopatin DE: Induction of β-defensisn resistance in the oral anaerobePorphyromonas gingivalis. Antimicrob Agents Chemother. 2005, 49: 183-187. 10.1128/AAC.49.1.183-187.2005.CrossRef
55.
Iovine NM, Elsbach P, Weiss J: An opsonic function of the neutrophil bactericidal/permeability increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci. 1997, 94: 10973-10978. 10.1073/pnas.94.20.10973.PubMedPubMedCentralCrossRef
56.
Zughaier SM, Shafer WM, Stephens DS: Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol. 2005, 7: 1251-1262. 10.1111/j.1462-5822.2005.00549.x.PubMedPubMedCentralCrossRef
57.
Gallicchio M, Benetti E, Rosa AC, Fantozzi R: Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. British J Pharmacol. 2009, 156: 486-496. 10.1111/j.1476-5381.2008.00033.x.CrossRef
58.
Schmitter T, Agerer F, Peterson L, Munzner P, Hauck CR: Granulocyte CEACAM3 is a phagocytic receptor of the innate immune system that mediates recognition and elimination of human-specific pathogens. J Exp Med. 2004, 199: 35-46.PubMedPubMedCentralCrossRef
59.
Underhill DM, Ozinsky A: Phagocytosis of microbes: complexity in action. Ann Rev Immunol. 2002, 20: 825-852. 10.1146/annurev.immunol.20.103001.114744.CrossRef
60.
Garcia-Garcia E, Rosales C: Signal transduction during Fc receptor-mediated phagocytosis. J Leuk Biol. 2002, 72: 1092-1108.
61.
Harzenetter MD, Keller U, Beer S, Riedl C, Peschel Ch, Holzmann B: Regulation and function of the CGRP receptor complex in human granulopoiesis. Exp Hematol. 2002, 30: 306-312. 10.1016/S0301-472X(02)00772-5.PubMedCrossRef
62.
Richter J, Andersson R, Edvinsson L, Gullberg U: Calcitonin gene-related peptide (CGRP) activates human neutrophils – inhibition by chemotactic peptide antagonist BOC-MLP. Immunology. 1992, 77: 416-421.PubMedPubMedCentral
63.
Ganea D, Delgado M: Neuropeptides as modulators of macrophage functions. Regulations of cytokine production and antigen presentation by VIP and PACAP. Arch Immun Ther Exp. 2001, 49: 101-110.
64.
Kaneider NC, Egger P, Djanani AM, Wiedermann ChJ: Leukocyte motility in response to neuropeptides is heperan sulfate proteoglycan dependent. Peptides. 2003, 24: 695-700. 10.1016/S0196-9781(03)00129-3.PubMedCrossRef
65.
Medina S, Del Rio M, Hernanz A, De la Fuente M: The NPY effects on murine leukocyte adherence and chemotaxis change with age. Adherent cell implication. Regul Pept. 2000, 95: 35-45.PubMedCrossRef
66.
Janiszewski J, Bienenstock J, Blennerhassett MG: Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. Am J Physiol Cell Physiol. 1994, 267: 138-145.
67.
Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Horsten S: Relevance of neuropeptide Y fo the neuroimmune crosstalk. J Neuroimmunol. 2003, 134: 1-11. 10.1016/S0165-5728(02)00424-1.PubMedCrossRef
68.
Braun A, Wiebe P, Pfeufer A, Geβner R, Renz H: Different modulation of human immunoglobulin isotype production by the neuropeptides substance P, NKA, and NKB. J Neuroimmunol. 1999, 97: 43-50. 10.1016/S0165-5728(99)00051-X.PubMedCrossRef
69.
Levite M, Cahalon L, Herskoviz R, Steinman L, Lider O: Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. J Immunol. 1998, 160: 993-1000.PubMed
70.
Kuo H-P, Lin H-Ch, Hwang K-H, Wang Ch-H LuL-Ch: Lipopolysaccharide enhances substance P-mediated neutrophil adherence to epithelial cells and cytokine release. Am J Respir Crit Care Med. 2000, 162: 1891-1897.PubMedCrossRef
71.
Lee H-Y, Andalibi A, Webster P, Moon S-K, Teufert K, Kang S-H, Li J-D, Nagura M, Ganz T, Lim DJ: Antimicrobial activity of innate immune molecules againstStreptococcus pneumonia,Moraxella catarrhalisand nontypeableHaemophilus influenzae. BMC Infect Dis. 2004, 4: 1-12. 10.1186/1471-2334-4-1.CrossRef
Metadata
Title
Innate immune properties of selected human neuropeptides against Moraxella catarrhalis and nontypeable Haemophilus influenzae
Authors
Daria Augustyniak
Adam Jankowski
Paweł Mackiewicz
Agnieszka Skowyra
Jan Gutowicz
Zuzanna Drulis-Kawa
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2012
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-13-24

Other articles of this Issue 1/2012

BMC Immunology 1/2012 Go to the issue

Research article

Adoptive transfer of IL-4Rα+ macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation

Review

Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond

Research article

DNA methylation profile of Aire-deficient mouse medullary thymic epithelial cells

Research article

Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia

Research article

Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis

Research article

Immune responses in the lungs of patients with tuberculous pleural effusion without pulmonary tuberculosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits